Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis (Q29619093)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1 reference

title

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19185342

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Toshi A Furukawa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Georgia Salanti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Julian Higgins

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Atsuo Nakagawa

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

10

Hugh McGuire

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Rachel Churchill

6

1 reference

ORCID Public Data File 2021

John R. Geddes

4

object named as

John R Geddes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

9

Ichiro M Omori

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

7

Norio Watanabe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

12

Corrado Barbui

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

11

Michele Tansella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19185342

20 January 2020

language of work or name

1 reference

30 April 2017

publication date

1 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19185342

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

373

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19185342

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

9665

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19185342

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

746-758

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

A systematic review and economic evaluation of statins for the prevention of coronary events.

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Are all antidepressants really the same? The case of fluoxetine: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Evaluation of networks of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Bayesian methods for evidence synthesis in cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Interpreting treatment effects in randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Imputing response rates from means and standard deviations in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Sifting the evidence-what's wrong with significance tests?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Controlled comparison of milnacipran and fluoxetine in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Mirtazapine compared with paroxetine in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A comparison of fluvoxamine and fluoxetine in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A comparative study of milnacipran and paroxetine in outpatients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Can discrete event simulation be of use in modelling major depression?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Symptom severity and exclusion from antidepressant efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Quality of Reporting of Randomized Trials as a Measure of Methodologic Quality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

"Wish bias" in antidepressant drug trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Full disclosure and the funding of biomedical research.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Placebo in clinical trials for depression: complexity and necessity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Clinical trials and the response rate illusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Placebo response in studies of major depression: variable, substantial, and growing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960046-5

7 January 2021

10.1016/S0140-6736(09)60046-5

Identifiers

DOI

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19185342

30 April 2017

Consolidated OpenCitations Corpus – April 2017

987579

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19185342%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

987579

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19185342

3 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

987579